Welcome to our dedicated page for Hillstream BioPharma news (Ticker: hils), a resource for investors and traders seeking the latest updates and insights on Hillstream BioPharma stock.
Hillstream BioPharma, Inc. (NASDAQ: HILS) is a cutting-edge biotechnology company dedicated to developing innovative therapeutic candidates targeting drug-resistant and devastating cancers. The company's proprietary Quatramer™ technology enables targeted delivery and extended action of biologics, mRNA, peptides, and other therapeutic modalities within the tumor microenvironment, minimizing off-target toxicity.
Hillstream's notable advancements include Quatrabody™ conjugates, which exhibit higher binding affinity to immuno-oncology targets than currently approved therapies. Emerging as a leader in immuno-oncology, Hillstream is set to enter the market with its leading candidate HSB-1940, targeting PD-1, followed by other targets such as PD-L1, HER-2, and TROP-2.
Recent achievements highlight Hillstream's exclusive license agreement with the Applied Biomedical Science Institute (ABSI), which allows the company to develop novel antibodies targeting HER2 and HER3. These antibodies are distinct from existing therapies and present a promising approach to treating HER2-positive cancers.
Hillstream's focus on oncology includes developing HSB-3215, a bi-specific antibody targeting HER2 and HER3. Through collaborations with Minotaur Therapeutics and OmniAb, Inc., Hillstream is advancing the development of next-generation biotherapeutics, including Picobodies™ against HER3 and other undisclosed oncology targets.
In addition to oncology, Hillstream is expanding its therapeutic pipeline with the acquisition of AV104, a clinical-stage asset for treating chronic pruritis, including conditions such as primary biliary cholangitis (PBC). This asset utilizes a proprietary transdermal buccal film for effective delivery and high drug concentrations in the skin.
Hillstream BioPharma's strategic focus on advancing its robust immuno-oncology pipeline and acquiring clinical-stage assets positions the company as a significant player in the biotechnology sector. For further information, please visit www.hillstreambio.com.
FAQ
What is the market cap of Hillstream BioPharma (hils)?
The market cap of Hillstream BioPharma (hils) is approximately 4.2M.
What does Hillstream BioPharma specialize in?
Hillstream BioPharma specializes in developing innovative therapeutic candidates targeting drug-resistant and devastating cancers, utilizing proprietary technologies like Quatramer™ and Quatrabody™.
What is the Quatramer™ technology?
Quatramer™ is Hillstream's proprietary tumor-targeting platform that extends the duration of action of biologics and other therapies while minimizing off-target toxicity.
What recent collaborations has Hillstream BioPharma announced?
Hillstream recently announced collaborations with the Applied Biomedical Science Institute for developing HER2 and HER3 antibodies and with Minotaur Therapeutics and OmniAb for Picobodies™ targeting HER3.
What is HSB-3215?
HSB-3215 is Hillstream's lead program, a bi-specific antibody targeting HER2 and HER3, designed to address drug-resistant cancers through novel conformational epitopes.
What is AV104?
AV104 is a clinical-stage asset acquired by Hillstream for treating chronic pruritis, particularly in primary biliary cholangitis patients. It employs a dual mechanism of action and proprietary buccal delivery system.
How does Hillstream plan to address unmet needs in oncology?
Hillstream aims to tackle unmet needs in oncology by developing novel bi-specific antibodies and ADCs targeting validated targets like HER2 and HER3, using proprietary technologies to enhance efficacy and safety.
What other therapeutic areas is Hillstream exploring?
Besides oncology, Hillstream is exploring treatments for chronic pruritis and other pruritogenic inflammatory conditions, leveraging assets like AV104 with novel delivery mechanisms.
What is the significance of Hillstream's collaboration with ABSI?
The collaboration with ABSI allows Hillstream access to novel antibodies targeting HER2 and HER3, distinct from current therapies, providing new treatment avenues for HER2-positive cancers.
What makes Picobodies™ unique?
Picobodies™ are derived from bovine antibodies and feature ultra-long CDR3 domains, allowing them to target previously inaccessible epitopes with greater specificity and binding potential.
Where can I find more information about Hillstream BioPharma?
More information about Hillstream BioPharma can be found on their official website, www.hillstreambio.com.